--- title: "INmune Bio (NASDAQ:INMB) Stock Price Down 1.3% - What's Next?" type: "News" locale: "en" url: "https://longbridge.com/en/news/297595042.md" description: "INmune Bio (NASDAQ:INMB) shares fell 1.3% to $2.30 on Monday, with trading volume down 25%. Analyst ratings remain mixed, averaging a 'Moderate Buy' despite recent upgrades from Wall Street Zen and Weiss Ratings. The company recently reported Q2 EPS of ($0.05), beating estimates. Institutional investors, including Charles Schwab and Wells Fargo, increased their positions in the fourth quarter, holding 12.72% of the stock." datetime: "2026-09-01T04:20:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297595042.md) - [en](https://longbridge.com/en/news/297595042.md) - [zh-HK](https://longbridge.com/zh-HK/news/297595042.md) generator: "portal-rs" --- # INmune Bio (NASDAQ:INMB) Stock Price Down 1.3% - What's Next? INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was down 1.3% during trading on Monday . The stock traded as low as $2.21 and last traded at $2.30. Approximately 294,749 shares were traded during trading, a decline of 25% from the average daily volume of 390,631 shares. The stock had previously closed at $2.33. ## Wall Street Analyst Weigh In INMB has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of INmune Bio from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of INmune Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy". **View Our Latest Analysis on INmune Bio** ## INmune Bio Stock Performance The stock has a market capitalization of $63.82 million, a PE ratio of -3.43 and a beta of 0.97. The firm's 50 day moving average is $1.92 and its two-hundred day moving average is $1.55. INmune Bio (NASDAQ:INMB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.16. ## Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently bought and sold shares of INMB. Quadrature Capital Ltd purchased a new stake in shares of INmune Bio during the fourth quarter worth approximately $26,000. Jain Global LLC acquired a new stake in shares of INmune Bio during the fourth quarter worth $66,000. Charles Schwab Investment Management Inc. grew its position in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company's stock valued at $78,000 after buying an additional 8,427 shares during the last quarter. Wells Fargo & Company MN grew its position in INmune Bio by 79.0% in the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company's stock valued at $39,000 after buying an additional 10,970 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in INmune Bio in the 4th quarter valued at $41,000. 12.72% of the stock is owned by hedge funds and other institutional investors. ## About INmune Bio (Get Free Report) INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company's research and development efforts concentrate on modulating cellular pathways to restore and enhance the body's natural defenses, particularly in oncology and neurodegenerative conditions. The company's lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions. ## Further Reading - Five stocks we like better than INmune Bio - Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season - Insiders Are Betting Big on These 3 Healthcare Stocks - 3 Stocks for Investors Who Still Believe Cash Is King - Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in INmune Bio Right Now? Before you consider INmune Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list. While INmune Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [INMB.US](https://longbridge.com/en/quote/INMB.US.md) - [WFC.US](https://longbridge.com/en/quote/WFC.US.md) - [SCHW.US](https://longbridge.com/en/quote/SCHW.US.md) - [BMO.US](https://longbridge.com/en/quote/BMO.US.md) - [DG.US](https://longbridge.com/en/quote/DG.US.md) - [DLTR.US](https://longbridge.com/en/quote/DLTR.US.md) - [SCHW-D.US](https://longbridge.com/en/quote/SCHW-D.US.md) - [SCHW-J.US](https://longbridge.com/en/quote/SCHW-J.US.md) - [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md) - [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md) - [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md) - [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md) - [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md) - [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md) ## Related News & Research - [INmune Bio to present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298454211.md) - [Concurrent Investment Advisors LLC Purchases 39,690 Shares of Wells Fargo & Company $WFC](https://longbridge.com/en/news/298126993.md) - [Braveheart Bio, Inc.'s Quiet Period To Expire on September 15th (NASDAQ:BRVE)](https://longbridge.com/en/news/298264807.md) - [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md) - [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**